Lupin announces strategic Co-marketing agreement with Boehringer Ingelheim
According to the agreement, Lupin will market and sell linagliptin under a separate brand name Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin) which will be promoted by Lupin’s 400 strong dedicated Diabetes specialty field force.